These consistent findings suggest that targeting well-characterized antigens like CTAG1B can significantly impact the therapeutic landscape for cancer, reinforcing the importance of ongoing research and development in TCR-T cell therapies to maximize clinical outcomes. Here, CTAG1B is linked to cancer.